ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VERA vs PRGO // REVENUE GROWTH (YOY)

Vera Therapeutics Inc. (Class A) (NASDAQ) VS. Perrigo Company plc (NYSE) • 15-METRIC TALLY: VERA 0 — PRGO 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VERA VS. PRGO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VERA PRGO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 35.10% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -13.60% -21.40 PRGO /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -10.99% 6.58% -17.57 PRGO /fcf-yield <GO>
Operating Margin — -26.40% — TIE /operating-margins <GO>
Net Profit Margin — -33.50% — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE — -2.80% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 7.22% -7.22 PRGO /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 PRGO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.8 55.3 -2.45 PRGO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.20B $2.21B -$6.3M PRGO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VERA REV PRGO REV VERA GROSS % PRGO GROSS % VERA FCF PRGO FCF
FY 2025 $0 $4.25B — 35.1% -$241.7M $145.1M
FY 2024 $0 $4.37B — 35.3% -$135.7M $244.6M
FY 2023 $0 $4.66B — — -$92.2M $405.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VERA // BETA —
PRGO // BETA —